Guardant Health, Inc. (GH) Year-over-year earnings per share growth for the last twelve months

Graphic logo of Guardant360 (GH)

Guardant Health, Inc. (GH) is a recognized leader in liquid biopsy, offering high-precision genetic diagnostics for personalized cancer treatment. The quarterly EPS growth assessment demonstrates profit dynamics, where the -24.70 indicator expresses the state of the metric. However, AI-driven DNA analysis automation is limited by the necessity of manual sampling, while the competition for rare bioinformaticians creates staffing pressure on the R&D segment.

Guardant Health (GH) - Year-over-year net earnings per share change for the last twelve months from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for Guardant Corp (GH)

- share price and consensus valuation forecast:
Stock Quotes Guardant Health|GH - Average Forecast Price
- market capitalization details:
Market Value Guardant360|GH - Company Buyout Price
- book capitalization data:
Book Value per Share Guardant Health|GH - Book Valuation of Business|Market Value to Book Value Ratio guardanthealth.com|GH - Company Total Asset Base
- debt level and financial liquidity data:
Total Debt to Capital Guardant Health, Inc.|GH - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Guardant Health, Inc.|GH - Company Aggregate Debts|Debts to Book Capitalization Guardant360|GH - Company Long-Term Debts|Company Short-Term Debt Guardant Health|Quick Ratio guardanthealth.com
- earnings and valuation multiples indicators:
GH - Company Profit|Projected Future Earnings Guardant Health, Inc.|GH - P/E Multiple|Future Price to Earnings Guardant360|GH - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Guardant360|GH - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Guardant Health|GH - Earnings per share for the trailing year|Quarterly EPS earnings growth guardanthealth.com|GH - Earnings per share increase in current year|Earnings growth forecast for next year Guardant Health, Inc.
- sales and revenue data:
GH - Company Total Revenue|Projected Sales Volume Guardant Health|GH - P/S Multiple|Price-to-Projected Revenue Ratio Guardant360
Initial company analysis:Guardant Health - GH
Flagship merchandise of guardanthealth.com

The market values Guardant Health, Inc. (GH) through the lens of its ability to monetize unique oncology patents. This metric measures the percentage change in net earnings per share per quarter, reflecting the efficiency of capital management. Analyzing the quarterly EPS trend allows for the identification of risks regarding declining returns or business stagnation. The company's strong pricing power in the liquid biopsy segment should support a positive trend. Stable growth of this indicator confirms the resilience of the business model amid inelastic demand.

Competitor analysis

CAI (Caris Life Sciences) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Veracyte Inc (VCYT)|Year-over-year earnings per share growth for the last twelve months Celcuity Corp|GRAIL Bio (GRAL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth MYGN|Year-over-year net earnings per share change for the last twelve months castlebiosciences.com|Year-over-year earnings per share growth for the last twelve months Burning Rock BNR|Year-over-year net earnings per share change for the last twelve months VolitionRx Ltd. (VNRX)|Biodesix Corp - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Precipio Inc (PRPO)|CHEK (check-cap.com) - Year-over-year net earnings per share growth for the last 12 months|mainzbiomed.com (MYNZ) - Quarterly EPS earnings growth|OCX (OncoCyte) - Quarterly EPS earnings growth